• "Biotech where science and spirit meet..."
Skip to content

{ Category Archives: } COVID-19

A look at Inovio’s Philly local coronavirus vaccine-in-progress

Operation Warp Speed, the federal government’s multi-agency push to develop a COVID-19 vaccine, is promising to provide 300 million doses by January 2021. That means funding for several of the top candidates. Moderna, one of the leaders of the pack, is already in Phase III trials after creating its first vaccine in a record-breaking 42…

Celularity announces the activation of first California Clinical Trial Site following CIRM Grant Award to Advance Treatments for COVID-19

FLORHAM PARK, N.J., Aug. 5, 2020 /PRNewswire/ — Celularity today announced that it has been awarded a $750,000 COVID-19 Project grant by the California Institute for Regenerative Medicine (CIRM), one of the three clinical awards targeting the coronavirus. This grant will support California Institutions participating in the Phase I/II clinical trial of human placental hematopoietic stem cell derived natural killer (NK)…

Pfizer could earn $15B-plus in COVID-19 vaccine sales: analyst

On the heels of Pfizer’s $1.95 billion COVID-19 vaccine deal with the U.S. government, one analyst says the drugmaker could earn many more billions in revenue on its potential vaccine—if the program succeeds. At $1.95 billion for 100 million doses, Pfizer’s deal sets a price-per-dose of $19.50, which Bloomberg Intelligence analyst Sam Fazeli sees as…

Novartis promises zero profit for 15 symptomatic COVID-19 drugs in low-income countries

Novartis’ generic hydroxychloroquine may have little use in COVID-19, but the Swiss pharma still wants to contribute its low-cost drugs in some way in the current fight. Novartis’ Sandoz unit will offer 15 generic and over-the-counter medicines at zero profit to developing countries during the pandemic, the company said Thursday. The portfolio covers widely used antibiotics and…

Here’s Why Inovio Is The Front-Runner In Developing a Coronavirus Vaccine

As of July 12, the number of new cases of COVID-19 in the U.S. has surpassed 60,000 for the fifth day in a row. Unfortunately, this rise cannot be attributed to increases in testing. For most of last week, nearly 1,000 Americans died each day due to COVID-19, representing a 300% increase from the death…

Gilead to donate 300,000 more remdesivir doses to US hospitals

Gilead will increase the number of doses of remdesivir it’s donating to the federal government in the next six weeks, STAT reported. The drugmaker had planned to donate 607,000 vials of remdesivir — the drug that received FDA emergency approval for use in treating COVID-19 patients after it was shown to shorten recovery time in patients with the virus…

Infectious-disease doctors ask government to explain how it decides who gets Gilead’s remdesivir

Within a week of the Food and Drug Administration’s authorization of remdesivir as a COVID-19 treatment, clinicians are pushing the Trump administration to clarify how it is selecting which hospitals get access to the drug. Shares of Gilead Sciences Inc. GILD, +0.18%, which developed remdesivir, edged up 0.2% in Thursday trades and are up 19.4% in 2020. MORE…

Regeneron scales up manufacturing, eyes human tests of COVID-19 antibody cocktail in June

As COVID-19 ravages across the globe, Regeneron has responded with its own two-pronged approach against the disease. After early results in China showed inhibiting IL-6 could manage a potentially deadly immune overreaction in serious COVID-19 patients, Regeneron and partner Sanofi started a phase 2/3 trial of their rheumatoid arthritis therapy Kevzara, following a similar move…

Marketing COVID-19 is bad news for new drug launches. Which will suffer most?

The COVID-19 pandemic and the ensuing societal countermeasures are upending operations in many sectors—and biopharma isn’t immune. The current lockdown is not only hurting clinical trial enrollment but also delaying regulatory timelines for drugs nearing a decision. And with tried-and-true, in-person marketing techniques no longer allowed, new launches may also feel the pain—or hold off altogether. Consider Bristol…

Amgen teams up with Adaptive to both treat and prevent COVID-19

After The Wall Street Journal first broke the news this week, Amgen and new partner Adaptive Biotechnologies have confirmed they are the latest pharma-biotech duo joining forces against the pandemic. The pair, which said it will “start work immediately,” will develop fully human neutralizing antibodies targeting the COVID-19-causing virus, SARS-CoV-2, to potentially prevent or treat…